Historical Valuation
Corbus Pharmaceuticals Holdings Inc (CRBP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 131.24 is considered Undervalued compared with the five-year average of -2.78. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between 114.67 to 120.52 according to relative valuation methord. Compared to the current price of 8.31 USD , Corbus Pharmaceuticals Holdings Inc is Undervalued By 92.75%.
Relative Value
Fair Zone
114.67-120.52
Current Price：8.31
92.75%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Corbus Pharmaceuticals Holdings Inc (CRBP) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 6.96 , the current P/B ratio is approximately -84.62% higher. Relative to its 5-year average P/B ratio of 4.81, the current P/B ratio is about -77.73% higher. Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward Free Cash Flow (FCF) yield of approximately -40.81%. Compared to its 3-year average FCF yield of -72.00%, the current FCF yield is approximately -43.31% lower. Relative to its 5-year average FCF yield of -81.25% , the current FCF yield is about -49.77% lower.
P/B
Median3y
6.96
Median5y
4.81
FCF Yield
Median3y
-72.00
Median5y
-81.25
Competitors Valuation Multiple
AI Analysis for CRBP
The average P/S ratio for CRBP competitors is 7730.84, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP.O) exhibits a P/S ratio of 131.24, which is -98.3% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CRBP
1Y
3Y
5Y
Market capitalization of CRBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRBP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CRBP currently overvalued or undervalued?
Corbus Pharmaceuticals Holdings Inc (CRBP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 131.24 is considered Undervalued compared with the five-year average of -2.78. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between 114.67 to 120.52 according to relative valuation methord. Compared to the current price of 8.31 USD , Corbus Pharmaceuticals Holdings Inc is Undervalued By 92.75% .
What is Corbus Pharmaceuticals Holdings Inc (CRBP) fair value?
CRBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between 114.67 to 120.52 according to relative valuation methord.
How does CRBP's valuation metrics compare to the industry average?
The average P/S ratio for CRBP's competitors is 7730.84, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP) exhibits a P/S ratio of 131.24, which is -98.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Jan 10 2026?
As of Jan 10 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a P/B ratio of 1.07. This indicates that the market values CRBP at 1.07 times its book value.
What is the current FCF Yield for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Jan 10 2026?
As of Jan 10 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a FCF Yield of -40.81%. This means that for every dollar of Corbus Pharmaceuticals Holdings Inc’s market capitalization, the company generates -40.81 cents in free cash flow.
What is the current Forward P/E ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Jan 10 2026?
As of Jan 10 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward P/E ratio of -1.31. This means the market is willing to pay $-1.31 for every dollar of Corbus Pharmaceuticals Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Jan 10 2026?
As of Jan 10 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward P/S ratio of 131.24. This means the market is valuing CRBP at $131.24 for every dollar of expected revenue over the next 12 months.